Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib
Clinical trial NCT06620835 · RECRUITING
Trial details
- NCT number
- NCT06620835
- Sponsor
- Groupe Francais De Pneumo-Cancerologie
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-19
- Primary completion
- 2030-10-01
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.